Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 20% vs ISMOTIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the extracellular fluid, thereby reducing intracranial pressure and promoting diuresis.
Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.
Reduction of intracranial pressure and cerebral edema,Reduction of intraocular pressure,Promotion of diuresis in acute renal failure (off-label)
Reduction of elevated intracranial pressure,Reduction of elevated intraocular pressure,Promotion of diuresis in acute renal failure (off-label)
Adult: 50-100 g intravenously as a 20% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV over 30-60 minutes. For oliguric acute kidney injury: test dose 0.2 g/kg IV over 3-5 minutes.
1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.
Terminal elimination half-life 1.1–1.6 hours in normal renal function; prolonged to 18–36 hours in anuria/end-stage renal disease.
4.5-6.0 hours in adults with normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria)
Minimal hepatic metabolism; primarily excreted unchanged by the kidneys.
Not significantly metabolized; primarily excreted unchanged by the kidneys.
Renal, >90% unchanged by glomerular filtration; negligible biliary (<2%) or fecal elimination.
Renal: 90-95% unchanged; biliary/fecal: <5%
Negligible (<0.1%); does not bind significantly to plasma proteins.
<10% (negligible), primarily albumin
0.25–0.4 L/kg; corresponds to extracellular fluid volume; increased in dehydration, decreased in hypervolemia.
0.5-0.7 L/kg; limited to extracellular fluid compartment
Intravenous: 100%; oral: <10% (non-absorbed, acts as osmotic laxative).
Oral: 60-70% (first-pass metabolism); Intravenous: 100%
GFR < 50 m L/min: avoid use due to risk of volume overload and hyperosmolality. GFR 50-80 m L/min: use with caution, monitor serum osmolarity. No specific dose reduction established.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: administer every 12 hours; GFR <10 m L/min: administer every 24 hours.
No adjustment required for Child-Pugh class A or B. Child-Pugh class C: use with caution due to potential fluid and electrolyte imbalances; monitor closely.
No adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Avoid in severe hepatic impairment (Child-Pugh C) due to risk of hepatic encephalopathy.
For cerebral edema: 0.25-1 g/kg IV as a 20% solution over 30-60 minutes. For elevated intracranial pressure: 0.25-0.5 g/kg IV. Maximum single dose typically 2 g/kg.
25-50 mg/kg orally every 6-8 hours, maximum 2 g/dose; or 25-50 mg/kg intravenously over 5-10 minutes every 6-8 hours, maximum 2 g/dose.
Elderly patients: lower initial doses (e.g., 25-50 g) recommended due to decreased renal function and higher risk of electrolyte disturbances. Monitor serum osmolarity and renal function closely.
Initiate at low end of dosing range (1 g every 8 hours) due to age-related renal function decline; adjust based on creatinine clearance.
None
None.
May cause volume expansion, electrolyte imbalances, and renal impairment; monitor serum electrolytes, osmolality, and renal function; use with caution in patients with heart failure or pulmonary congestion.
Monitor renal function and serum electrolytes,Avoid in patients with anuria or severe renal impairment,Risk of pulmonary edema, heart failure, and electrolyte disturbances
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, and known hypersensitivity.
Anuria,Severe renal failure,Congestive heart failure,Active intracranial bleeding (except during craniotomy),Hypovolemia
No known food interactions; however, monitor fluid and electrolyte balance as mannitol induces diuresis.
Avoid high-tyramine foods (aged cheeses, cured meats, soy products) as hydralazine may increase tyramine sensitivity? No significant specific food interactions for isosorbide dinitrate/hydralazine. However, limit high-salt foods to manage heart failure. Avoid alcohol due to additive hypotensive effects.
Mannitol is not teratogenic in animal studies. In human pregnancy, there are no controlled studies; FDA pregnancy category C. First trimester: theoretical risk due to osmotic shifts, but no documented fetal harm. Second and third trimesters: use only if clearly needed; may cause maternal dehydration and electrolyte disturbances, potentially affecting fetal fluid balance. Avoid in severe maternal renal impairment.
No adequate and well-controlled studies in pregnant women. In animal studies, administration of isosorbide dinitrate (active ingredient of Ismotic) during organogenesis produced fetal toxicity at doses 35 times the maximum human dose. First trimester: unknown risk, avoid unless clearly needed. Second and third trimesters: risk of maternal hypotension and reduced placental perfusion; use only if potential benefit justifies risk. Should be used with caution near term due to risk of neonatal hypotension.
Mannitol is excreted into breast milk in trace amounts; M/P ratio not established. Oral bioavailability is low, so infant exposure via breastfeeding is minimal. Compatible with breastfeeding; caution if infant has renal impairment.
Isosorbide dinitrate is excreted in human breast milk; clinical significance unknown. M/P ratio not reported. Caution is advised; consider temporary discontinuation of breastfeeding during therapy.
No specific dose adjustments required; pharmacokinetics of mannitol are not significantly altered by pregnancy. Use standard dosing based on indication and renal function. Caution in preeclampsia due to potential for fluid shifts.
Pregnancy may alter pharmacokinetics: increased plasma volume and renal clearance may reduce drug concentrations. However, no specific dose adjustments are recommended; titrate based on clinical response and tolerability. Start at lowest effective dose, increase cautiously. Avoid rapid dose escalation. Consider lower doses in third trimester due to increased sensitivity to vasodilation.
Monitor serum osmolarity and sodium levels frequently; avoid use in patients with anuria, severe pulmonary congestion, or intracranial hemorrhage. Mannitol may cause acute kidney injury if used in high doses or in patients with pre-existing renal impairment. Administer via in-line filter to prevent crystallization.
ISOMOTIC (isosorbide dinitrate/hydralazine) is a fixed-dose combination for heart failure in self-identified Black patients. Monitor for hypotension, headache, and dizziness. Avoid use with PDE-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Titrate gradually to target dose to minimize adverse effects. May cause drug-induced lupus-like syndrome or peripheral neuropathy with hydralazine; consider slow acetylator phenotype risk.
This medication is given intravenously to reduce swelling in the brain or to promote urine output.,Report any signs of allergic reaction, chest tightness, or difficulty breathing immediately.,You may experience increased thirst, headache, or nausea during infusion.,Inform your healthcare provider if you have kidney problems, heart failure, or are pregnant.
Take this medication exactly as prescribed to control your heart failure symptoms.,Do not take erectile dysfunction medicines (like sildenafil, tadalafil) while on this drug, as it can cause a dangerous drop in blood pressure.,You may experience headaches, dizziness, or lightheadedness when starting; these often improve over time. If severe, contact your doctor.,Avoid alcohol, which can worsen dizziness and low blood pressure.,Report any unexplained joint pain, fever, rash, or numbness/tingling in your hands or feet to your doctor immediately.,Swallow tablets whole; do not crush or chew.,Do not stop suddenly without consulting your doctor; abrupt discontinuation can worsen heart failure.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 20% vs ISMOTIC, answered by our medical review team.
MANNITOL 20% is a Osmotic Diuretic that works by Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the extracellular fluid, thereby reducing intracranial pressure and promoting diuresis.. ISMOTIC is a Osmotic Diuretic that works by Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 20% and ISMOTIC depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 20% is: Adult: 50-100 g intravenously as a 20% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV over 30-60 minutes. For oliguric acute kidney injury: test dose 0.2 g/kg IV over 3-5 minutes.. The standard adult dose of ISMOTIC is: 1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MANNITOL 20% and ISMOTIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MANNITOL 20% is classified as Category A/B. Mannitol is not teratogenic in animal studies. In human pregnancy, there are no controlled studies; FDA pregnancy category C. First trimester: theoretical risk due to osmotic shift. ISMOTIC is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal studies, administration of isosorbide dinitrate (active ingredient of Ismotic) during organogenesis produced fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.